BioSpace News Archive

Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today announced that Derek Chalmers, Ph.D., D.Sc., President and Chief Executive Officer, will participate in the following upcoming virtual investor conferences and events in November and December: Stifel 2020 V

- Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth , President and Chief Executive Officer, will present at the Stephens Annual Investment Conference 2020 on Tuesday, November 17, 2020 at 3:00 p.m. EST . A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne’s Investor Rela

Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health”) and its gastroenterology (GI) business, Salix Pharmaceuticals, (“Salix”), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointes

As the need to improve efficiency and speed in trials grows, more than 75 organizations, including six of the top 20 pharmaceutical companies, are unifying clinical information and processes with Veeva Vault CTMS . More emerging biotechs and global organizations have adopted the modern cloud application from Veeva Sys

Abiomed, Inc . (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will hold a fireside chat at the Stephens Annual Investment Conference 2020 (virtual) on Wednesday, November 18, 2020 at 9:00am ET. ABOUT ABIOMED Based in Danvers, Massachusetts, Abiomed, Inc. is a leading provider of medical de

Results for our CD19-targeted CAR T cell therapy lisocabtagene maraleucel (liso-cel) in patients with heavily pretreated mantle cell lymphoma and relapsed/refractory chronic lymphocytic leukemia Data showcasing BCMA-targeted CAR T cell therapy idecabtagene vicleucel (ide-cel), including updated results from the Phase 1 CRB-401 study

– Deciphera Presents the First and Largest Baseline Genomic Analysis by Tumor and Liquid Biopsy in Fourth-line Patients with GIST – – Results from an Exploratory Analysis of the Phase 3 INVICTUS Study in Fourth-line GIST Demonstrate the Broad Clinical Activity of QINLOCK Across Mutation Sub-groups –

Interim data from Phase 1 dose expansion cohort of mRNA-4157 in combination with pembrolizumab shared at The Society for Immunotherapy of Cancer’s Annual Meeting 2020 Data support expansion of Head and Neck Squamous Cell Carcinoma (HNSCC) cancer patient cohort Praveen Aanur, MBBS joins Moderna as Vice President, Therapeutic Area Head for Oncology Development

Aleafia Health Inc. (TSX: AH, OTC: ALEAF) (“ Aleafia Health” or the “ Company ”) is pleased to report its financial results for the three and nine months ended September 30, 2020 (“ Q3 2020 ”). “We expect to have our strongest quarter to date in Q4 2020 as we progress towards significant sequential growth in medical, adult-use, wholesale and international cannabis sales. The strategic path we’ve executed upon, from building out facilities, to receiv

Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an update about the Company’s progress at the Jefferies 2020 Virtual London Healthcare Conference on Wednesday, November 18, 2020, at 2:40 PM GMT/9:40 AM ET.